Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes

Practical Diabetes International

Volumn 22, Issue 1, 2005, Pages 10-14

  Pickup, John C ^a   Kidd, Julia ^b   Burmiston, Sheila ^b   Yemane, Nardos ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Continuous subcutaneous insulin infusion; Guidelines; Hypoglycaemia; Insulin pump therapy; Type 1 diabetes

Indexed keywords

ASPART; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC LOAD; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MALE; MICROANGIOPATHY; PATIENT SELECTION; PRACTICE GUIDELINE; RISK; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

EID: 18644364317     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.732     Document Type: Article

References (28)

1. Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; i: 204-207.
2. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
3. Guidance on the Use of Continuous Subcutaneous Insulin Infusion for Diabetes. Technology Appraisal Guidance No. 57. London: National Institute for Clinical Excellence, 2003.
4. Tsui E, Barnie A, Ross S, et al. Intensive insulin therapy with insulin lispro. A randomized trial of continuous subcutaneous insulin infusion versus multiple daily injection. Diabetes Care 2001; 24: 1722-1727.
5. Hannaire-Broutin H, Melki V, Bessierre-Lacombe S, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000; 23: 1232-1235.
6. Bending JJ, Pickup JC, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Am J Med 1985; 79: 685-691.
7. Dahl-Jørgensen K, Brinchman-Hansen O, Hanssen KF, et al. Effect of near-normoglycaemia for two years on the progression of early diabetic retinopathy: the Oslo Study. BMJ 1986; 293: 1195-1199.
8. Haardt MJ, Berne C, Dorange C, et al. Efficacy and indications of CSII revisited: the Hôtel Dieu cohort. Diabetic Med 1997; 14: 407-408.
9. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784.
10. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327.
11. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-751.
12. Pickup JC, Mattock MB, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared to intensive insulin injection therapy in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 705-708.
13. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 1993; 329: 977-986.
14. Bolli GB. Insulin treatment and its complications. In Textbook of Diabetes, 3rd edn. Pickup JC, Williams G (eds). Oxford: Blackwell Publishing, 2003; 43.1-43.20.
15. Pickup JC. Alternative forms of insulin delivery. In Textbook of Diabetes, 3rd edn. Pickup JC, Williams G (eds). Oxford: Blackwell Publishing, 2003; 44.1-44.15.
16. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987; 10: 225-237.
17. Shima K, Tanaka R, Morishita S, et al. Studies on the etiology of 'brittle diabetes': relationship between diabetic instability and insulinogenic reserve. Diabetes 1977; 26: 717-725.
18. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor control. Diabetes Care 2002; 25: 2074-2080.
19. Diabetes Control and Complications Trial Group. Implementation of treatment protocols on the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361-376.
20. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
21. Raskin P, Kaff L, Bergenstall R, et al. A 16-week comparison of the novel insulin analogue insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
22. King AB, Armstrong D. A comparison of basal insulin delivery. Continuous subcutaneous insulin infusion versus glargine. Diabetes Care 2003; 26: 1322.
23. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in type 1 diabetes. Diabetic Med 2003; 20: 1012-1015.
24. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion. A comprehensive review of insulin pump therapy. Arch Intern Med 2001; 161: 2293-2300.
25. Cable G. Enhancing causal interpretations of quality improvement interventions. Qual Health Care 2001; 10: 179-186.
26. Glasziou P, Vandenbroucke J, Chalmers I. Assessing the quality of research. BMJ 2004; 328: 39-41.
27. Vandenbroucke JP. Observational research and evidence-based medicine: what should we teach young physicians? J Clin Epidemiol 1998; 51: 467-472.
28. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.